Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Jenesse Nicole Moffett"'
Autor:
Konstantinos Leventakos, Anastasios Dimou, Nathan R. Foster, Lynn M. Flickinger, Sri Harsha Tella, Julian R. Molina, Aaron Scott Mansfield, Randolph Marks, Anna J Schwecke, Craig Hocum, Jenesse Nicole Moffett, Ashley Potter, Alex A. Adjei
Publikováno v:
Journal of Clinical Oncology. 40:TPS8604-TPS8604
TPS8604 Background: Chemoimmunotherapy followed by durvalumab maintenance yields a median overall survival of 12.9 months in patients with extensive stage Small Cell Lung Cancer (ES SCLC), which is an improvement over chemotherapy alone. However, 90%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebdac8aa280518c00b2ebe619b849f00
https://doi.org/10.1200/jco.2022.40.16_suppl.tps8604
https://doi.org/10.1200/jco.2022.40.16_suppl.tps8604
Autor:
Pranitha Prodduturvar, Craig L. Hocum, Ashley L. Potter, S.S. Park, Yolanda I. Garces, Anna Schwecke, Dawn Owen, Konstantinos Leventakos, Kenneth R. Olivier, R.W. Gao, Julian R. Molina, Aaron S. Mansfield, Anastasios Dimou, Randolph S. Marks, Kenneth W. Merrell, Jenesse Nicole Moffett, Alex A. Adjei
Publikováno v:
Journal of Clinical Oncology. 39:e20554-e20554
e20554 Background: The paradigm for locally advanced non-small cell lung cancer has been markedly altered to include maintenance durvalumab (D) post completion of definitive chemoradiation (CRT) following the publication of the Pacific trial in 2018.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ddc9bae85bb09b6e54945796d08f9d09
https://doi.org/10.1200/jco.2021.39.15_suppl.e20554
https://doi.org/10.1200/jco.2021.39.15_suppl.e20554